(NASDAQ: OGI) Organigram Global's forecast annual revenue growth rate of 22.69% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 135.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Organigram Global's revenue in 2025 is $187,813,768.On average, 5 Wall Street analysts forecast OGI's revenue for 2026 to be $41,953,185,658, with the lowest OGI revenue forecast at $39,715,754,136, and the highest OGI revenue forecast at $44,670,643,054. On average, 5 Wall Street analysts forecast OGI's revenue for 2027 to be $44,479,708,393, with the lowest OGI revenue forecast at $42,417,076,208, and the highest OGI revenue forecast at $46,731,930,629.
In 2028, OGI is forecast to generate $46,458,974,740 in revenue, with the lowest revenue forecast at $45,079,404,583 and the highest revenue forecast at $48,299,746,227.